Merck & Co Overvaluation Concerns Amid Dividend Sustainability Questions

Merck & Co Inc (NYSE: MRK) announced on September 21, 2026, that Japan's Ministry of Health, Labor and Welfare has approved its Keytruda Qlex injection for subcutaneous administration across all previously approved indications. This new formulation, marketed as Keyject in Japan, offers patients a more convenient dosing schedule and faster administration times.

The company currently offers a dividend yield of 2.31%, which is modest but attractive for income-focused investors in the healthcare sector. However, the payout ratio of 1.05 (105%) raises red flags regarding the sustainability of this dividend. A payout ratio exceeding 100% suggests that dividends are being paid out of retained earnings or debt rather than earnings.

The stock trades at a historically elevated P/E ratio of 117.4x compared to its 5-year median of 20.19x, and is currently 21.6% overvalued relative to its GF Value™ of $120.75 per share. Merck’s dividend growth rate has been steady at 5.4% over the past three years, indicating management’s commitment to rewarding shareholders despite recent earnings volatility.

GuruFocus’ proprietary GF Score™ model estimates Merck’s intrinsic value at $120.75 per share, while the stock currently trades at $146.87. This 21.6% premium categorizes MRK as modestly overvalued, implying that the market may be pricing in optimistic growth or premium valuation multiples.

Investors should carefully consider these factors before committing capital, especially if dividend safety is a priority. Insider activity reveals no insider buying and significant insider selling totaling $71.4 million over the past 12 months.